Eisai's core pharma business grew double digits in Q1, lifting revenue to ¥234.3 billion. Operating margin lands near 10.5% with Leqembi launch costs in view.
First-quarter revenue at Eisai Co., Ltd. (ESAIY) rose 15.6% to JPY 234.3 billion, and operating profit reached JPY 24.7 billion, the company said Monday.
Chief Financial Officer Takuya Oyama delivered the figures on the earnings call for the three months ended June 30, the first quarter of fiscal 2026, which ends in March 2027. Operating profit equaled roughly 10.5% of quarterly revenue. The session ran in hybrid format, with materials posted on Eisai's website. Chief Growth Officer Keisuke Naito was to follow Oyama with the business overview.
The growth came from the pharmaceutical segment, Eisai's core operation. Oyama called it "our organic business" and said it "grew significantly, achieving double-digit revenue growth." The gain came from prescription sales, in the company's framing. Pharmaceutical products account for the large majority of Eisai's revenue, so the segment's pace sets the group's.
Leqembi, the Alzheimer's treatment developed with Biogen, is Eisai's principal growth product. Eisai leads development, with Biogen sharing in the economics. The drug launched in the U.S. in 2023 and is approved in Japan and China as well. Eli Lilly's Kisunla, approved in the U.S. in 2024, is the main competing antibody in the class. Both drugs require confirmed amyloid pathology and MRI monitoring during treatment, so the rollout has proceeded slowly, site by site. Eisai carries the launch's selling costs regardless of quarterly volume. The U.S. is Leqembi's largest market, and Tatsuyuki Yasuno, president of the Americas region, took part in the call. CEO Haruo Naito and Chief Scientific Officer Katsutoshi Ido also joined. Analysts from seven firms participated, including Hidemaru Yamaguchi of Citigroup and Seiji Wakao of JPMorgan.
Japan's National Health Insurance system reprices reimbursed drugs each April, so the April-June quarter is the first under fiscal 2026 levels. Those levels apply through next March and set the pricing baseline for Eisai's domestic sales for the rest of the fiscal year. Eisai books a large share of pharmaceutical revenue outside Japan, so currency moves feed directly into the yen-reported results.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.